AstraZeneca (NYSE:AZN) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS

AstraZeneca (NYSE:AZN) issued its quarterly earnings data on Friday. The company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of $2.60 by $0.19, FiscalAI reports. The business had revenue of $16.21 billion during the quarter, compared to analysts’ expectations of $16 billion. AstraZeneca had a net margin of 17.02% and a return on equity of 31.45%. The business’s revenue was up 6.5% on a year-over-year basis. During the same period last year, the company posted $2.38 EPS.

Here are the key takeaways from AstraZeneca’s conference call:

• Strong underlying growth continued: nine-month revenue rose 7% and core EPS increased 14%, while revenue excluding Farxiga and Brilinta grew 12%. Oncology, rare disease, and respiratory/immunology delivered double-digit growth, offsetting expected loss-of-exclusivity pressures.
• AstraZeneca reported 12 positive Phase III readouts and four new-medicine approvals so far in 2026, supporting confidence in its $80 billion 2030 revenue ambition. Management highlighted more than 20 major Phase III readouts in 2027, representing over $20 billion in non-risk-adjusted peak-sales potential.
• Oncology momentum remained especially strong, with revenue up 16% year to date; Tagrisso exceeded $2 billion in quarterly sales, while Imfinzi/Imjudo, Calquence, and Enhertu posted robust growth. Positive data for Tagrisso combinations, Sone-Ve, Imfinzi-based regimens, and Enhertu could support further franchise expansion.
• AstraZeneca launched a three-year “Reshaping for Sustainable Growth” program involving up to $2 billion in restructuring costs, although it targets $1.5 billion of annualized pre-tax savings for reinvestment. Management also flagged ongoing headwinds from Farxiga, Brilinta, and SYMBICORT loss of exclusivity, China volume-based procurement, higher fourth-quarter expenses, and increased capital expenditure.

AstraZeneca Trading Up 6.9%

AZN traded up $12.09 on Friday, hitting $186.49. The company had a trading volume of 5,464,384 shares, compared to its average volume of 2,974,251. The company’s fifty day moving average price is $164.48 and its 200 day moving average price is $180.21. AstraZeneca has a 1 year low of $153.41 and a 1 year high of $212.71. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. The firm has a market cap of $289.23 billion, a P/E ratio of 27.88, a PEG ratio of 1.35 and a beta of 0.27.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AZN. Weiss Ratings raised shares of AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday. Zacks Research raised AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Royal Bank Of Canada assumed coverage on AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Finally, HSBC downgraded AstraZeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

More AstraZeneca News

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
• Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
• Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
• Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
• Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
• Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.